- Trials with a EudraCT protocol (3)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
3 result(s) found for: Internal limiting membrane.
Displaying page 1 of 1.
| EudraCT Number: 2021-003226-71 | Sponsor Protocol Number: MR42410 | Start Date*: 2022-01-31 | |||||||||||
| Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A PHASE IIIB, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFECTIVENESS AND SAFETY OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB VS AFLIBERCEPT TREAT & ... | |||||||||||||
| Medical condition: Neovascular Age-Related Macular Degeneration (AMD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) FI (Completed) HU (Completed) DK (Completed) PT (Completed) GR (Completed) IE (Completed) NL (Completed) DE (Completed) AT (Completed) PL (Prematurely Ended) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-003883-28 | Sponsor Protocol Number: SB15-3001 | Start Date*: 2020-05-28 | |||||||||||
| Sponsor Name:Samsung Bioepis Co., Ltd. | |||||||||||||
| Full Title: A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB15 (proposed aflibercept biosimilar) and Eyl... | |||||||||||||
| Medical condition: Neovascular age-related macular degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LV (Completed) CZ (Completed) HU (Completed) HR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-000362-42 | Sponsor Protocol Number: THR-687-002 | Start Date*: 2021-10-06 | ||||||||||||||||
| Sponsor Name:Oxurion NV | ||||||||||||||||||
| Full Title: A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-687 injections and to evaluate the efficacy and safety of THR-687 versus aflibercept for the treatment of diabetic ... | ||||||||||||||||||
| Medical condition: Diabetic macular oedema (DME) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: SK (Prematurely Ended) LT (Completed) LV (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) DE (Ongoing) IT (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.